Achillion disappoints investors with lackluster IPO

Achillion Pharmaceuticals went public, raising $51.8 million in its IPO. But the results were well below the established price range. The company sold 30 percent of its equity at $11.50 a share compared to a forecast of $14 to $16 a share. This is just the latest in a string of lackluster public openings and tends to underscore the weak market conditions that still prevails for biotech stocks. Trubion went public just days ago, trading at the bottom of its forecasted price range. Achillion was a 2003 Fierce 15 company.

- here's the report on Achillion's IPO from

Suggested Articles

The clamor for more transparency from the leading pandemic vaccine contenders has been getting louder.

The role gives one of the driving forces behind Bristol Myers Squibb’s $74 billion takeover of Celgene the chance to help build biotechs.

The appointment gives Sino-American biotech Brii the experience of a man who helped Gilead launch eight drugs in China in quick succession.